R Squared’s Spyre Therapeutics SYRE Stock Holding History

R Squared’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-710	Closed	-$16.5K	–	1374
2024 Q4	$16.5K	Buy	+710	New	+$20.8K	0.02%	964

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

R Squared's SYRE Position: Q1 2025 in Review

R Squared sold out of Spyre Therapeutics (SYRE) in Q1 2025, closing a stake of 710 shares — an estimated $16.5K sold.

R Squared first reported a position in SYRE in Q4 2024 and held it in 1 quarter. The position peaked at $16.5K in Q4 2024. 129 funds tracked by Wall St. Rank hold SYRE as of Q1 2025.

R Squared reported no remaining Spyre Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 710 Spyre Therapeutics shares in Q1 2025, an estimated $16.5K.
R Squared first reported a position in Spyre Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Spyre Therapeutics position peaked at $16.5K in Q4 2024.
129 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.